Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
Year: 2018
Type: article
Abstract: No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.
Source: Neuro-Oncology
Authors: Raymond Y Huang, Wenya Linda Bi, Michael Weller, Thomas Kaley, Jaishri Blakeley, Ian Dunn, Evanthia Galanis, Matthias Preusser, Michael McDermott, Leland Rogers, Jeffrey Raizer, David Schiff, Riccardo Soffietti, Jörg-Christian Tonn, Michael Vogelbaum, Damien Weber, David A Reardon, Patrick Y Wen
Institutions: Brigham and Women's Hospital, University Hospital Zurich, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, Mayo Clinic, Vienna General Hospital, Comprehensive Cancer Center Vienna, Medical University of Vienna, University of California, San Francisco, Barrow Neurological Institute, Northwestern Medicine, University of Virginia, University of Turin, Ludwig-Maximilians-Universität München, Cleveland Clinic, Paul Scherrer Institute, Center for Neuro-Oncology, Dana-Farber Brigham Cancer Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2885037385